(This commentary was not written by CRD, but by the authors of the DH Register.)
1) Side-effects are reported to be frequent and minor. 2) From the mortality data it may be possible to calculate life-years gained. 3) Outcome uncertainties are handled with an extensive sensitivity analysis and results for high risk groups are presented. 4) Net cost savings are heavily influenced by production gain. 5) The authors note that costs prediction over 30-40 years is difficult because of possible technological advances.